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A B S T R A C T
Electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) techniques for liquid
chromatography–tandem mass spectrometry (LC–MS/MS) determination of levonorgestrel were evaluated. In
consideration of diﬀerence in ionization mechanism, the two ionization sources were compared in terms of LC
conditions, MS parameters and performance of method. The sensitivity for detection of levonorgestrel with ESI
was 0.25 ng/mL which was lower than 1 ng/mL with APCI. Matrix eﬀects were evaluated for levonorgestrel and
canrenone (internal standard, IS) in human plasma, and the results showed that APCI source appeared to be
slightly less liable to matrix eﬀect than ESI source. With an overall consideration, ESI was chosen as a better
ionization technique for rapid and sensitive quantiﬁcation of levonorgestrel. The optimized LC–ESI–MS/MS
method was validated for a linear range of 0.25–50 ng/mL with a correlation coeﬃcient ≥0.99. The intra- and
inter-batch precision and accuracy were within 11.72% and 6.58%, respectively. The application of this method
was demonstrated by a bioequivalence study following a single oral administration of 1.5 mg levonorgestrel
tablets in 21 Chinese healthy female volunteers.
1. Introduction
Levonorgestrel (Fig. 1A) is the most widely used synthetic female
contraceptive hormone in pregnancy prevention in humans [1]. Racemic
mixture was ﬁrst synthesized in the 1950s, and the biologically active
levorotary enantiomer is levonorgestrel. It has strong progestational and
anti-ovulatory activities with no estrogenic eﬀects [2]. Levonorgestrel is
quickly and completely absorbed into systemic circulation after oral
administration (bioavailability about 100%) [3]. As the use of oral
contraceptives has increased globally, requirements of monitoring the
pharmacokinetic behavior are gaining great importance [4].
Several methods have been reported for the determination of the
concentration of levonorgestrel in animal [5] or human plasma [6–10].
Electrospray ionization (ESI) and atmospheric pressure chemical ioniza-
tion (APCI) are the most commonly used atmospheric pressure ionization
sources for qualitative or quantitative liquid chromatography tandem
mass spectrometry (LC–MS/MS) analysis. Both ESI and APCI sources
have been reported for determination of levonorgestrel. Solid phase
extraction (SPE)–LC–MS/MS was used to determine levonorgestrel in
human plasma with APCI as ionization source [7]. A large plasma volume
(2 mL) was required to obtain a lower limit of quantiﬁcation (LLOQ) by
high condensation. An LC–MS/MS method was developed using ESI
source with LLOQ of 0.25 ng/mL [8]. Although the runtime for each
injection was only 2 min, serious matrix eﬀects might occur when a large
amount of human plasma samples was analyzed. Neither of these two
experiments investigated matrix eﬀects. Online SPE–LC–MS/MS with
ESI source was applied for the simultaneous determination of six most
frequently used synthetic progestins in human plasma samples, including
levonorgestrel [9]. This method covered a quantiﬁcation concentration
range of 2–100 ng/mL, which was maladaptive for human pharmacoki-
netic study. A more sensitive LC–ESI–MS/MS method was developed for
the quantiﬁcation of levonorgestrel in human plasma by chemical
derivatization using hydroxylamine [10]. Although the LLOQ was
0.1 ng/mL in this method, derivatization made the sample preparation
complex and time consuming.
In this work, we evaluated two common ionization sources of LC–
MS/MS system, ESI and APCI, in the analysis of levonorgestrel in
human plasma with canrenone (Fig.1B) as internal standard (IS).
Methods for both ESI and APCI sources were developed and optimized.
Liquid-liquid extraction (LLE) with cyclohexane was employed.
Linearity, quantitation limitation and the presence of matrix eﬀects
in both cases were discussed. LC–ESI–MS/MS method was chosen for
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a bioequivalence study in 21 Chinese healthy female volunteers
following oral administration of levonorgestrel at the dose of 1.5 mg.
2. Experimental
2.1. Chemicals and reagents
Levonorgestrel reference standard (Batch No: 100076-201205) was
purchased from the National Institutes for Food and Drug Control (Beijing,
China). Canrenone reference standard (Batch No: 101202-201001) was
purchased from the National Institute for the Control of Pharmaceutical
and Biological Products (Beijing, China). HPLC-grade methanol was from
Merck (Darmstadt, Germany). Formic acid, sodium bicarbonate and
cyclohexane of analytical grade were procured from Nanjing Chemical
Reagents Co., Ltd. (Nanjing, China). Deionized water was puriﬁed using a
Milli-Q Water Puriﬁcation System (Merck Millipore, Darmstadt, Germany)
after distilled twice and used throughout the experiment.
2.2. Preparation of stock and working solutions
The standard stock solutions of levonorgestrel and IS were pre-
pared in methanol at the concentration of 1 mg/mL respectively and
then stored at 4 °C. The working solutions of levonorgestrel used for
calibration and quality control (QC) were prepared daily by further
dilution of the standard stock solution in methanol:water (80:20, v/v).
The IS working solution was prepared freshly by diluting the standard
stock solution to 200 ng/mL.
2.3. LC–MS/MS instrumentation and conditions
The liquid chromatographic separation and mass spectrometric
detection were achieved by employing the Nexera UHPLC system
coupled to an LCMS-8040 tandem quadrupole mass spectrometer
(Shimadzu, Kyoto, Japan). Labsolutions LCMS software (Shimadzu)
was used to control the instruments and process the data. The Nexera
UHPLC system used in the analysis consisted of a system controller
Fig. 1. The chemical structures of (A) levonorgestrel and (B) canrenone.
Fig. 2. Representative chromatograms of blank plasma in (A) ESI source and (B) APCI source.
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(CBM-20A), two pumps (LC-30CE), an autosampler (SIL-30AC), a
column heater (CTO-20A), and a degasser (DGU-20A5R).
This instrument was equipped with both ESI and APCI sources.
Chromatographic separation was performed using a Shimadzu Shim-pack
VP-OSD C18 column (150 mm×2.0 mm, 4.6 µm) at a ﬂow rate of 0.2 mL/
min in ESI source, and a Shimadzu Shim-pack VP-OSD C18 column
(150 mm×4.6 mm, 4.6 µm) at a ﬂow rate of 1.0 mL/min in APCI source.
The isocratic mobile phase consisted of methanol and 0.01% formic acid
(80:20, v/v). The mass spectrometer operating parameters were optimized
as follows: interface voltage, 4.5 kV; nebulizer gas ﬂow, 3 L/min; drying
gas ﬂow, 15 L/min; desolvation line (DL) temperature, 250 °C; heat block
temperature, 400 °C in ESI source, 200 °C in APCI source. The APCI
temperature was 350 °C. Other parameters were tuned automatically.
2.4. Sample preparation
All the samples were stored in the freezer at −20 °C, and allowed to
thaw at ambient temperature prior to analysis. LLE was chosen to
Fig. 3. Representative chromatograms of blank plasma spiked with levonorgestrel at lower limit of quantitation (0.25 ng/mL with ESI source, 1 ng/mL with APCI source) and IS in (A)
ESI source and (B) APCI source.
Table 1
Comparison of calibration curves for levonorgestrel by ESI and APCI (n=3).
Conc. added (ng/mL) ESIa ACPIb
Back-calculated Conc. (ng/mL) RSD (%) Accuracy (%) Back-calculated Conc. (ng/mL) RSD (%) Accuracy (%)
0.25 0.25 11.48 99.4 ND ND ND
0.5 0.51 8.74 101.7 ND ND ND
1 1.04 6.80 103.6 1.07 9.96 107.6
2 1.85 11.18 92.5 1.83 6.14 91.7
5 4.79 8.32 95.9 4.25 13.06 85.0
8 8.06 11.90 100.7 7.14 6.41 89.2
10 10.41 7.41 104.1 10.56 9.15 105.6
20 22.34 12.46 111.7 22.36 8.61 111.8
50 45.90 6.36 91.8 51.15 7.55 102.3
Y: Concentration of levonorgestrel added to the plasma.
X: Peak area ratios (peak area of analyte/peak area of internal standard).
ND: not detected.
a Y=12.175X−0.3340, r=0.99487.
b Y=9.4884X+0.5426, r=0.99076.
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prepare the samples. To a 500 µL aliquot human plasma in a 10 mL
glass tube, 10 µL of the IS working solution (200 ng/mL), 100 µL of the
saturated sodium bicarbonate and 4 mL of cyclohexane were added.
The mixture was vortex-mixed thoroughly for 3 min, and then cen-
trifuged at 4000 rpm for 10 min. The upper organic layer was
transferred to another 10 mL clean glass tube and evaporated to
dryness at 40 °C under a steady stream of nitrogen. The residue was
reconstituted in 150 µL mobile phase, and vortex-mixed for 1 min.
After centrifuging at 14,000 rpm for 10 min, a 10 µL of the supernatant
was injected into the LC–MS/MS system for analysis.
2.5. Calibration curve and QC samples
Calibration standards were prepared by spiking 0.5 mL blank
human plasma with proper volume of levonorgestrel working solutions,
producing levonorgestrel plasma concentrations of 0.25, 0.5, 1, 2, 5, 8,
10, 20, and 50 ng/mL. QC samples were prepared by spiking blank
plasma with proper volume of the working solutions to produce a ﬁnal
concentration equivalent to 0.5 ng/mL (low level), 5 ng/mL (middle
level) and 20 ng/mL (high level) of levonorgestrel. These samples with
known amounts of levonorgestrel were extracted as described in the
section “Sample preparation”. In each run, two blank samples (pro-
cessed with or without the IS, respectively) were analyzed to conﬁrm
absence of interferences but not used to construct the calibration
function. Calibration curves were constructed by determining the best
ﬁt of peak area ratios (peak area of analyte/peak area of IS), where X
Fig. 4. Representative chromatograms for levonorgestrel and the IS resulting from analysis of 5 ng/mL of levonorgestrel in human plasma with (A) ESI source and (B) APCI source.
Table 2
Matrix effects for levonorgestrel and canrenone by ESI and APCI (n=5).
Concentration (ng/
mL)
ESI APCI
Matrix eﬀect
(%)
RSD (%) Matrix effect
(%)
RSD (%)
Levonorgestrel
0.5 131.74 6.28 ND ND
5 128.12 3.28 104.66 8.65
20 125.13 4.27 99.17 8.37
Canrenone
0.4 126.17 4.04 123.14 5.13
ND: not detected.
Table 3
The intra- and inter-batch precision and accuracy of the method for the determination of levonorgestrel.
Conc. added (ng/mL) Intra-batch (n=5) Inter-batch (n=15)
Determined Conc. (ng/mL) RSD (%) Accuracy (%) Determined Conc. (ng/mL) RSD (%) Accuracy (%)
0.5 0.51 11.72 101.77 0.50 9.95 99.20
5 4.67 5.06 93.42 4.75 8.26 94.91
20 20.08 7.71 100.42 19.51 6.48 97.54
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corresponds to the peak area ratio and Y refers to the concentration of
levonorgestrel added to the plasma. The weighted factor of levonorges-
trel was 1/Y2.
3. Results and discussion
3.1. Choice of LC conditions
A Shimadzu Shim-pack VP-OSD C18 column (150 mm×2.0 mm,
4.6 µm) at a ﬂow rate of 0.2 mL/min was used in ESI source. The
chromatographic conditions, especially the composition of the mobile
phase, were optimized through several trials. With the method of
orthogonal experimental design, three concentration levels of formic
acid and ammonium acetate buﬀer in aqueous phase were investigated.
Diﬀerent ratios of methanol as organic phase were also considered.
Base on these results, the adopted mobile phase is a mixture of
methanol and 0.01% formic acid (80:20, v/v) for balancing the
chromatographic separation and MS/MS sensitivity. This condition
successfully separated IS and levonorgestrel at retention time of 3.4
and 4.0 min, respectively, which avoided the interference of ionization
between them. In APCI source, abovementioned mobile phase compo-
sitions were investigated as well. Similar results were obtained, so the
same mobile phase was used as ESI source. Since the column eﬄuent
ﬂow-rate has to be considered an important factor for the sensitivity of
LC–APCI–MS methods [11,12], ﬂow rates of 0.2, 0.5 and 1.0 mL/min
were investigated by two inner diameter sizes of Shimadzu Shim-pack
VP-OSD C18 column (150 mm×2.0 mm and 150 mm×4.6 mm) respec-
tively. The sensitivity with APCI source was observed to increase when
the solvent ﬂow rate increased. Therefore, a Shimadzu Shim-pack VP-
OSD C18 column (150 mm×4.6 mm, 4.6 µm) at a ﬂow rate of 1.0 mL/
min was used in APCI source.
3.2. Optimization of MS parameters (ESI and APCI)
The working parameters of ESI and APCI ionization sources for
detection of levonorgestrel and IS were optimized automatically by
injecting 1 µL of the standard solutions (1 µg/mL) into diﬀerent
sources separately and the MS/MS spectra were recorded and com-
pared. Both the positive and negative modes were investigated in two
sources. The response of positive ions was stronger than that of
negative ions no matter which source was used, which indicated that
the positive mode was much more sensitive. Therefore, all detections
were operated in a positive multiple-reaction monitoring (MRM) mode.
The optimized results of product ions m/z were 245.10, 109.10, and
91.10, corresponding to collision energies of 19 V, 28 V and 48 V in
priority. With ESI source, there was strong interference when pre-
cursor to product transition m/z 313.10→245.10 was used for detect-
ing low concentration levonorgestrel in plasma. Therefore, m/z
313.10→109.10 was chosen for quantiﬁcation of levonorgestrel with
ESI source while m/z 313.10→245.10 was chosen with APCI source.
The precursor to product transition m/z 341.10→107.10 for IS was
used in both two sources as optimal result. There was no endogenous
interference present at the retention time of 4.0 min for levonorgestrel
and 3.4 min for IS.
3.3. Method performance
3.3.1. Speciﬁcity
Blank plasma used to assay the speciﬁcity of the method was
obtained from six healthy individuals. Speciﬁcity was investigated by
comparing the chromatograms of blank human plasma (Fig. 2) with
those of spiked human plasma samples in which the concentration of
levonorgestrel closed to the LLOQ (Fig. 3). In all the tested six blank
human plasma chromatograms, no endogenous compounds peak was
observed at the retention time of levonorgestrel and IS in both APCI
and ESI sources.
3.3.2. Linearity and quantiﬁcation limits
Levonorgestrel calibration standard solutions were analyzed from
three replicate analyses by ESI and APCI, respectively. Calibration
Table 4
The stability of levonorgestrel in human plasma at different QC levels (n=3).
Conditions Concentration levels (ng/mL) Accuracy (%, mean ± SD)
Nominal Determined
Short-term
stability (8 h at
room
temperature)
0.5 0.53 105.86 ± 4.43
5 4.95 98.91 ± 9.95
20 18.07 90.33 ± 3.90
Post-extraction
stability (48 h
at room
temperature)
0.5 0.49 98.19 ± 7.71
5 5.03 100.50 ± 10.72
20 18.84 94.21 ± 7.27
Post-preparative
stability (24 h
in
autosampler)
0.5 0.52 103.97 ± 8.62
5 5.06 101.10 ± 9.30
20 18.44 92.21 ± 4.74
Three repeated
freeze (−20 °C)
and thaw
(room
temperature)
stability
0.5 0.52 104.54 ± 6.10
5 4.91 98.27 ± 9.00
20 19.65 98.24 ± 9.10
Long-term
stability (32
days at −20 °C)
0.5 0.51 102.06 ± 7.01
5 5.18 103.50 ± 8.68
20 19.00 94.99 ± 6.14
Fig. 5. Mean plasma concentration-time curve of levonorgestrel in 21 volunteers after
oral administration at the dose of 1.5 mg.
Table 5
Pharmacokinetic parameters of levonorgestrel in 21 women after oral administration
(mean ± SD).
Parameters Test tablets Reference tablets
Cmax (ng/mL) 13.07 ± 2.58 12.88 ± 2.27
Tmax (h) 1.7 ± 0.6 1.7 ± 0.7
t1/2 (Kel)(h) 21.43 ± 3.63 19.44 ± 3.90
MRT0→∞ (h) 25.07 ± 3.92 22.77 ± 4.19
AUC0→72 (ng h/mL) 138.77 ± 36.79 138.83 ± 31.71
AUC0→∞ (ng h/mL) 151.88 ± 38.47 149.51 ± 33.44
Cmax: maximum plasma concentration.
Tmax: time to reach Cmax.
t1/2: elimination half-life.
MRT0→∞: mean residence time from time zero to inﬁnity.
AUC0→72: the area under the plasma concentration-time curve from time zero to the last
sampling time.
AUC0→∞: the area under the plasma concentration-time curve from time zero to
inﬁnity.Ke: elimination rate constant.
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curves were prepared on three diﬀerent days. With ESI source, the
calibration curves showed good linearity in the range of 0.25–50 ng/
mL, while the range with APCI was just 1–50 ng/mL. Results of three
representative calibration curves for LC–MS/MS determination of
levonorgestrel are given in Table 1. The representative chromatograms
for levonorgestrel and the IS resulting from analysis of 5 ng/mL of
levonorgestrel in human plasma with ESI and APCI sources are shown
in Fig. 4.
The LLOQ was assessed by repeatedly analyzing the spiked plasma
samples in ﬁve replicates, in which the deviation was within ± 20% of
the nominal concentration. The LLOQ of levonorgestrel was 0.25 ng/
mL with ESI source while 1 ng/mL with APCI source.
3.3.3. Matrix eﬀects
LC–MS/MS is a perfect strategy for biological sample analysis
because of its precision, robustness, high sensitivity and selectivity.
However, one limitation of LC–MS/MS that has been increasingly
taken into consideration in recent years is the matrix eﬀect [13–15].
Both ESI and APCI have been reported to suﬀer from this phenomenon
[16]. To evaluate the matrix eﬀects for the two sources, the peak areas
of the levonorgestrel dissolved in blank sample (the ﬁnal solution of
blank plasma after being extracted and redissolved) were compared
with those obtained by injection of standard solutions at the same
concentration. The matrix eﬀect of IS (4 ng/mL in plasma) was
performed in the same way. The matrix eﬀect values for levonorgestrel
and IS with ESI and APCI sources are shown in Table 2. The blank
human plasma used in this assay was obtained from diﬀerent sources.
The results indicated that APCI was less susceptible to matrix eﬀect
than ESI source. This ﬁnding is in agreement with previously reported
[17,18].
3.4. Summary of comparison
Analytes in liquid stream are converted into gas phase ions in both
ESI and APCI sources to adapt the mass spectrometer detection
[19,20]. However, the way to produce ionized analyte is very diﬀerent.
In ESI, analyte is ionized in the liquid phase inside the electrically
charged droplets, and then analyte ions in solution are liberated from
the liquid phase into the gas phase [21]. In APCI, the neutral analyte is
transferred into the gas phase by vaporizing the liquid in a heated gas
stream, and the gas phase analyte is chemically ionized in a separate
step [22]. So mobile phase composition, speciﬁcity, linearity, quanti-
ﬁcation limits and matrix eﬀects were taken into consideration in this
comparison study. Both ESI and APCI sources in this experiment have
no endogenous substances and metabolites interfering with the assay
of levonorgestrel and IS. The LC–ESI–MS/MS method was proved to
be more sensitive for measuring levonorgestrel in human plasma with
an LLOQ at 0.25 ng/mL, while APCI at 1 ng/mL. ESI showed a small
but constant matrix eﬀect in diﬀerent concentrations of levonorgestrel
in plasma (0.5, 5 and 20 ng/mL), while APCI showed scarcely any
matrix eﬀect. Since levonorgestrel has low blood level after oral
administration, ESI source was employed in human pharmacokinetic
study.
3.5. Robustness and ruggedness
Robustness and ruggedness were determined to evaluate the
inﬂuence of small but deliberate variation in the chromatographic
conditions. The robustness of the method was evaluated in ﬂow rate,
mobile phase composition and injection volume. In method develop-
ment, it was found that slight changes in ﬂow rate ( ± 0.01 mL/mL) and
mobile phase composition (ratio of methanol in mobile phase ± 1%)
had no signiﬁcant inﬂuence in peak area value of levonorgestrel and IS.
Injection volume had almost no eﬀect on response of analyte and IS,
either. Ruggedness was investigated when the instrument was changed
to the Finnigan™ TSQ Quantum Discovery MAX™ LC–MS/MS system.
Variations of chromatographic behavior and MS response were accep-
table. Because of this, it is feasible to perform method validation and
pharmacokinetics study in the Finnigan™ TSQ Quantum Discovery
MAX™ LC–MS/MS system which equipped with ESI source.
3.6. Validation of the LC–ESI–MS/MS method
The LC–ESI–MS/MS method was validated following the United
States Food and Drug Administration bioanalytical method validation
guidance [23].
Speciﬁcity, linearity and matrix eﬀect had been investigated in the
previous comparison study.
The precision and accuracy of intra-batch were determined by
analyzing ﬁve sets of spiked plasma samples of levonorgestrel at each
QC level (0.5, 5 and 20 ng/mL) in a batch. The precision and accuracy
of inter-batch were determined by analyzing ﬁve sets of spiked plasma
samples of levonorgestrel at each QC level on three consecutive
batches. The concentration of each sample was calculated by the
calibration curve prepared and analyzed in the same day. Results are
shown in Table 3. The intra- and inter-batch precision was in the range
of 5.06%–11.72% and 6.48%–9.95%, respectively. The intra- and inter-
batch accuracy was within the range of 93.42%–101.77% and 94.91%–
99.20%, respectively.
The absolute extraction recovery of levonorgestrel was assessed by
comparing the analyte and IS peak area ratios in processed samples to
blank plasma extracts spiked with parallel concentration solutions.
This procedure was repeated (n=5) at each QC level. The extraction
recovery determined for levonorgestrel was consistent, precise and
reproducible. The mean recoveries of levonorgestrel at the three
concentration levels were 80.21%, 77.37% and 82.95%, respectively,
whereas the RSDs were 6.21%, 2.80% and 13.73%, respectively. The
mean absolute extraction recovery of the IS was 72.74%± 11.44% at
the concentration used in the assay (4 ng/mL).
The stability of levonorgestrel in human plasma under diﬀerent
conditions was assessed by simulating conditions that might occur
during the experiment. Table 4 summarizes the results of stability
experiments of levonorgestrel. The results showed the reliable stability
behavior of levonorgestrel under the tested conditions. The stability of
levonorgestrel and IS in stock solutions were also examined and no
obvious reduction was found during the assay.
3.7. Application in pharmacokinetics study
The validated method was successfully applied to a pharmacoki-
netic study following oral administration of levonorgestrel at the dose
of 1.5 mg. A total of 21 Chinese healthy female volunteers took part in
the pharmacokinetic study (Ethical Committee License Number:
YW20140321-03). Blood samples (4 mL) were collected before intake
and at 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24, 48, and 72 h after oral
administration. The samples were put into lithium heparin tubes and
were immediately centrifuged at 3000 rpm for 10 min. The plasma
obtained was frozen at −20 °C in coded polypropylene tubes until
analysis. The pharmacokinetic parameters were calculated using the
Drug and Statistics (DAS) version 2.0 software (Mathematical
Pharmacology Professional Committee of China, Shanghai, China).
All the mean plasma concentration-time proﬁles of 21 volunteers are
represented in Fig. 5. Pharmacokinetic parameters of the test orally
tablet and reference tablet are listed in Table 5. The test tablets were
found to be bioequivalence to the reference ones.
3.8. Incurred sample reanalysis (ISR)
The quality of the bioanalytical assay was assessed by ISR. 24
samples were chosen for ISR per period, and 48 in whole pharmaco-
kinetics study. All samples met the criteria of being close to the
maximum concentration or near the LLOQ. Those selected samples
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had percentage diﬀerence from −17.66% to 19.77%, as well as 11.80%
for mean deviation. The results authenticated the reproducibility of the
proposed method.
4. Conclusion
Two ionization techniques, ESI and APCI for LC–MS/MS system
were compared for quantiﬁcation of levonorgestrel. The LLOQ, linear-
ity, and matrix eﬀects were evaluated for levonorgestrel in human
plasma. The results show that APCI source was less aﬀected by the
ionization suppression produced by sample matrix components, but
the LLOQ of levonorgestrel for the ESI source was lower than that for
the APCI source. This rule can be widely applied to quantiﬁcation of
endogenous and exogenous progestogens.
The results show that the ESI source is more attractive because high
sensitivity was obtained. An LC–ESI–MS/MS method was validated for
the quantiﬁcation of levonorgestrel in human plasma. The method was
rapid, selective and highly sensitive with an LLOQ at 0.25 ng/mL for
levonorgestrel. The analysis time is only 5.0 min for each run. The
simple preparation, rapid separation, and good reproducibility of
analysis are the most outstanding characteristics of this method. The
method has been successfully applied to evaluate the pharmacokinetics
of levonorgestrel following oral administration at the dose of 1.5 mg to
healthy Chinese female volunteers.
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